The availability of novel biological resources [30 (link),31 (link)] is helpful in the design of novel therapeutics against human pathogens [32 (link),33 (link)]. The shortlisting of highly antigenic target proteins and epitope sequences predicted against each protein of the HCMV were retrieved from the previously developed online resource [31 (link)], whereas the antigenic and non-antigenic proteins for each specie were identified with a VaxiJen threshold scoring system [34 (link)]. The online available VaxiJen server (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html ; accessed on 11 September 2022) utilizes an alignment free, covariance-based approach with a focus on the amino acids properties [34 (link)]. Proteins were further subjected to allergenicity prediction analysis. The performed allergenicity check helps to ensure the prevention of possible allergic responses in the host [32 (link)] during the vaccine designing procedures. Algpred v. 2.0 (http://crdd.osdd.net/raghava/algpred/ ; accessed on 27 September 2022) server [33 (link)] was utilized to evaluate allergenicity status of the proteins. The input sequence was added as a single letter amino acid code while the selected prediction approach was an amino acid composition based SVM module [33 (link)]. The analyzed shortlisted epitopes for each target protein with potential efficacy are already available in the online resource for potential utility in vaccine construction. Further analysis was performed on the basis of shortlisted epitopes against each target protein from the HCMV proteome. All the retrieved information of the genomic data set (NCBI accession ID: NC_006273.2) and proteome (UniProt accession ID: UP000000938) of Human herpesvirus were collected and subjected to further analysis. The overall workflow of the performed study is shown in Figure 1 .
Free full text: Click here
